(CLX) The Clorox - Overview
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 11.501m USD | Total Return: -22.2% in 12m
Avg Turnover: 272M
EPS Trend: 72.7%
Qual. Beats: 0
Rev. Trend: -75.4%
Qual. Beats: 0
Warnings
Altman Z'' 0.85 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
The Clorox Company (NYSE: CLX) is a global manufacturer and marketer of consumer and professional products, organized into four primary segments: Health and Wellness, Household, Lifestyle, and International. Its portfolio includes market-leading brands such as Clorox, Pine-Sol, Glad, Kingsford, Brita, and Burts Bees. The company utilizes an omni-channel distribution strategy, selling through mass retailers, grocery stores, e-commerce platforms, and professional distributors.
Operating within the defensive Household Products sub-industry, Clorox relies on a brand-heavy business model where high consumer loyalty provides stable demand across various economic cycles. The company’s diversification into vitamins, minerals, and supplements through brands like RenewLife reflects a strategic expansion into the high-margin health and wellness category. Examining the historical valuation trends on ValueRay can help determine if the current stock price reflects these long-term growth drivers.
Founded in 1913 and headquartered in Oakland, California, the company maintains a significant presence in both domestic and international markets. Its International segment mirrors its domestic offerings, adapting core categories like home care and water filtration for global consumers.
- Raw material and logistics costs impact gross margins across core cleaning segments
- Market share recovery following the 2023 cybersecurity breach drives revenue stabilization
- Consumer trade-down to private labels threatens premium brand volume and pricing power
- Advertising and promotion spending levels determine competitive positioning in household categories
- Fluctuating demand for disinfecting products affects Health and Wellness segment organic growth
| Net Income: 756.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -8.63 > 1.0 |
| NWC/Revenue: -7.46% < 20% (prev -8.05%; Δ 0.59% < -1%) |
| CFO/TA 0.09 > 3% & CFO 576.0m > Net Income 756.0m |
| Net Debt (3.71b) to EBITDA (1.31b): 2.83 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.8m) vs 12m ago -1.84% < -2% |
| Gross Margin: 43.85% > 18% (prev 0.45%; Δ 4.34k% > 0.5%) |
| Asset Turnover: 113.2% > 50% (prev 127.3%; Δ -14.18% > 0%) |
| Interest Coverage Ratio: 11.19 > 6 (EBITDA TTM 1.31b / Interest Expense TTM 97.0m) |
| A: -0.08 (Total Current Assets 2.65b - Total Current Liabilities 3.15b) / Total Assets 6.44b |
| B: 0.03 (Retained Earnings 223.0m / Total Assets 6.44b) |
| C: 0.18 (EBIT TTM 1.08b / Avg Total Assets 5.97b) |
| D: 0.03 (Book Value of Equity 202.0m / Total Liabilities 6.34b) |
| Altman-Z'' = 0.85 = B |
| DSRI: 1.17 (Receivables 671.0m/597.0m, Revenue 6.76b/7.02b) |
| GMI: 1.03 (GM 43.85% / 45.03%) |
| AQI: 0.81 (AQ_t 0.34 / AQ_t-1 0.42) |
| SGI: 0.96 (Revenue 6.76b / 7.02b) |
| TATA: 0.03 (NI 756.0m - CFO 576.0m) / TA 6.44b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of May 28, 2026, the stock is trading at USD 97.11 with a total of 2,082,109 shares traded.
Over the past week, the price has changed by +4.90%,
over one month by +0.47%,
over three months by -22.67% and
over the past year by -22.15%.
The Clorox has received a consensus analysts rating of 3.05. Therefore, it is recommended to hold CLX.
- StrongBuy: 2
- Buy: 2
- Hold: 13
- Sell: 3
- StrongSell: 1
| Analysts Target Price | 105.3 | 8.4% |
P/E Trailing = 15.465
P/E Forward = 13.8696
P/S = 1.7024
P/B = 46.5805
P/EG = 1.9803
Revenue TTM = 6.76b USD
EBIT TTM = 1.08b USD
EBITDA TTM = 1.31b USD
Long Term Debt = 2.49b USD (from longTermDebt, last quarter)
Short Term Debt = 1.68b USD (from shortTermDebt, last quarter)
Debt = 4.89b USD (from shortLongTermDebtTotal, last quarter) + Leases 408.0m
Net Debt = 3.71b USD (calculated: Debt 4.89b - CCE 1.19b)
Enterprise Value = 15.2b USD (11.5b + Debt 4.89b - CCE 1.19b)
Interest Coverage Ratio = 11.19 (Ebit TTM 1.08b / Interest Expense TTM 97.0m)
EV/FCF = 40.02x (Enterprise Value 15.2b / FCF TTM 380.0m)
FCF Yield = 2.50% (FCF TTM 380.0m / Enterprise Value 15.2b)
FCF Margin = 5.62% (FCF TTM 380.0m / Revenue TTM 6.76b)
Net Margin = 11.18% (Net Income TTM 756.0m / Revenue TTM 6.76b)
Gross Margin = 43.85% ((Revenue TTM 6.76b - Cost of Revenue TTM 3.80b) / Revenue TTM)
Gross Margin QoQ = 43.23% (prev 43.16%)
Tobins Q-Ratio = 2.36 (Enterprise Value 15.2b / Total Assets 6.44b)
Interest Expense / Debt = 1.98% (Interest Expense 97.0m / Debt 4.89b)
Taxrate = 25.39% (65.0m / 256.0m)
NOPAT = 809.5m (EBIT 1.08b * (1 - 25.39%))
Current Ratio = 0.84 (Total Current Assets 2.65b / Total Current Liabilities 3.15b)
Debt / Equity = -73.04 (negative equity) (Debt 4.89b / totalStockholderEquity, last quarter -67.0m)
Debt / EBITDA = 2.83 (Net Debt 3.71b / EBITDA 1.31b)
Debt / FCF = 9.76 (Net Debt 3.71b / FCF TTM 380.0m)
Total Stockholder Equity = 147.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 12.65% (Net Income 756.0m / Total Assets 6.44b)
RoE = 514.3% (Net Income TTM 756.0m / Total Stockholder Equity 147.0m)
RoCE = 41.19% (EBIT 1.08b / Capital Employed (Equity 147.0m + L.T.Debt 2.49b))
RoIC = 16.59% (NOPAT 809.5m / Invested Capital 4.88b)
WACC = 4.91% (E(11.5b)/V(16.4b) * Re(6.37%) + D(4.89b)/V(16.4b) * Rd(1.98%) * (1-Tc(0.25)))
Discount Rate = 6.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.33 | Cagr: -1.02%
[DCF] Terminal Value 73.10% ; FCFF base≈548.4m ; Y1≈480.9m ; Y5≈388.6m
[DCF] Fair Price = 20.92 (EV 6.24b - Net Debt 3.71b = Equity 2.53b / Shares 120.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 72.74 | EPS CAGR: 12.76% | SUE: 0.38 | # QB: 0
Revenue Correlation: -75.36 | Revenue CAGR: -2.79% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-09-30): EPS=1.29 | Chg30d=-2.86% | Revisions=-67% | Analysts=11
EPS current Year (2026-06-30): EPS=5.54 | Chg30d=-5.16% | Revisions=-33% | GrowthEPS=-28.2% | GrowthRev=-5.9%
EPS next Year (2027-06-30): EPS=6.29 | Chg30d=-6.21% | Revisions=-50% | GrowthEPS=+13.7% | GrowthRev=+13.4%
[Analyst] Revisions Ratio: -67%